Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Leukemia, Promyelocytic, Acute 20Leukemia, Myeloid, Acute 20Myelodysplastic Syndromes 9Multiple Myeloma 9Leukemia 8Pancreatic Neoplasms 4Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Neuroblastoma 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thrombocytopenia 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pathologic Complete Response 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Hodgkin Disease 2Hematologic Neoplasms 2Congenital Abnormalities 2Colorectal Neoplasms 2Breast Neoplasms 2Blast Crisis 2

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × Tretinoin × Clear all
NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

University of Iowa

Phase 2 Withdrawn
CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡